Suppliers and packagers for generic pharmaceutical drug: PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE

PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
King Pharms Llc	BICILLIN C-R	penicillin g benzathine; penicillin g procaine	INJECTABLE;INJECTION	050138	NDA	Pfizer Laboratories Div Pfizer Inc	60793-600-10	10 SYRINGE in 1 PACKAGE (60793-600-10) / 2 mL in 1 SYRINGE (60793-600-02)	1953-05-18
King Pharms Llc	BICILLIN C-R	penicillin g benzathine; penicillin g procaine	INJECTABLE;INJECTION	050138	NDA	Pfizer Laboratories Div Pfizer Inc	60793-601-10	10 SYRINGE in 1 PACKAGE (60793-601-10) / 2 mL in 1 SYRINGE (60793-601-02)	1953-05-18
King Pharms Llc	BICILLIN C-R	penicillin g benzathine; penicillin g procaine	INJECTABLE;INJECTION	050138	NDA	Pfizer Laboratories Div Pfizer Inc	60793-602-10	10 SYRINGE in 1 PACKAGE (60793-602-10) / 2 mL in 1 SYRINGE (60793-602-02)	1953-05-18

Penicillin G Benzathine and Penicillin G Procaine Drug Substance Suppliers Analysis

Last updated: February 19, 2026

This report identifies and analyzes key suppliers for the pharmaceutical drug substances Penicillin G Benzathine and Penicillin G Procaine. The analysis focuses on manufacturing capabilities, regulatory compliance, and geographical presence to inform R&D and investment decisions.

Who are the primary manufacturers of Penicillin G Benzathine and Penicillin G Procaine drug substances?

The global supply chain for Penicillin G Benzathine and Penicillin G Procaine drug substances is concentrated among a limited number of specialized manufacturers. These entities possess the complex fermentation and chemical synthesis capabilities required for their production.

Key manufacturers include:

• Sandoz GmbH (Austria): A subsidiary of Novartis, Sandoz is a significant player in generic pharmaceuticals and active pharmaceutical ingredients (APIs). They operate a large-scale manufacturing facility in Kundl, Austria, historically a major penicillin production site. Their capabilities encompass fermentation and downstream processing for various antibiotics, including penicillins.

• Centrient Pharmaceuticals (Netherlands): Formerly Lek Pharmaceuticals, Centrient Pharmaceuticals is a global producer of beta-lactam antibiotics and cephalosporins. They have manufacturing sites in Europe and Asia, with a strong focus on quality and regulatory compliance. Their production of penicillins is a core business area.

• Taj Pharmaceuticals Limited (India): Taj Pharmaceuticals is an Indian pharmaceutical company with API manufacturing facilities. They are known to produce a range of antibiotics, including penicillins. Their facilities are typically subject to inspections by international regulatory bodies.

• Anhui Dejia-Bio Pharmaceutical Co., Ltd. (China): This Chinese company is a producer of various pharmaceutical intermediates and APIs. They are listed as a supplier of penicillin derivatives, including those used in injectable formulations.

• Qingdao EON PHARMA Co., Ltd. (China): Another Chinese entity, Qingdao EON PHARMA supplies a variety of APIs. Their product portfolio includes antibiotics, and they are positioned as a source for penicillin-related drug substances.

These manufacturers differ in scale, geographical reach, and the specific grades and volumes of Penicillin G Benzathine and Penicillin G Procaine they offer. The choice of supplier often depends on factors such as regulatory approval status in target markets, required production volumes, and pricing.

What are the regulatory and quality standards for these drug substances?

Manufacturing of Penicillin G Benzathine and Penicillin G Procaine drug substances must adhere to stringent global regulatory standards to ensure patient safety and product efficacy. The primary frameworks are Current Good Manufacturing Practices (cGMP) as defined by regulatory agencies like the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others.

Key regulatory considerations include:

• FDA Registration and Inspection: Manufacturers supplying to the U.S. market must be registered with the FDA. Their facilities undergo regular inspections to ensure compliance with 21 CFR Part 210 and 211. Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP) are also highly valued.

• EMA Compliance: For the European market, compliance with EMA guidelines and holding a CEP are critical. Inspections by national competent authorities within the EU are standard.

• Pharmacopoeial Standards: Drug substances must meet the specifications outlined in major pharmacopoeias, including the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP). These monographs define identity, purity, assay, and other critical quality attributes.

• ICH Guidelines: Compliance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, particularly those related to quality (e.g., ICH Q7 for API GMP), is essential for global market access.

• Traceability and Supply Chain Integrity: Robust systems for raw material sourcing, process control, and finished product testing are mandatory. Full traceability from raw material to final API batch is required.

• Impurity Profiling: Manufacturers must rigorously control and monitor impurities, including process-related impurities and potential genotoxic impurities. This requires validated analytical methods and defined acceptance criteria.

The presence of a Drug Master File (DMF) filed with regulatory authorities (e.g., FDA DMF or ASMF for Europe) is a strong indicator of a manufacturer's commitment to regulatory compliance and provides detailed information about the manufacturing process, quality control, and stability of the API.

What are the key manufacturing processes and challenges?

The production of Penicillin G Benzathine and Penicillin G Procaine involves distinct stages, each presenting unique technical and logistical challenges. Both are salts of Penicillin G, requiring specific chemical synthesis steps after the initial fermentation process.

Penicillin G Benzathine Synthesis:

1. Fermentation: Production begins with the fermentation of Penicillium chrysogenum to yield Penicillin G. This is a complex bioprocess requiring precise control of temperature, pH, aeration, and nutrient supply. Strain improvement and optimization of fermentation media are crucial for high yields and purity.
2. Isolation and Purification of Penicillin G: Following fermentation, Penicillin G is extracted from the broth and purified. This typically involves solvent extraction, precipitation, and crystallization.
3. Salt Formation (Benzathine): Purified Penicillin G is then reacted with N,N'-dibenzylethylenediamine (benzathine) under controlled conditions to form Penicillin G Benzathine. This step requires careful management of reaction stoichiometry, solvent systems, and temperature to ensure complete reaction and minimize by-products.
4. Crystallization and Drying: The Penicillin G Benzathine salt is crystallized to achieve the desired particle size distribution and polymorphic form. Subsequent drying must be performed under conditions that preserve the integrity of the molecule and prevent degradation.

Penicillin G Procaine Synthesis:

1. Fermentation and Purification of Penicillin G: Same as for Penicillin G Benzathine.
2. Salt Formation (Procaine): Purified Penicillin G is reacted with procaine (2-(diethylamino)ethyl 4-aminobenzoate) under controlled conditions to form Penicillin G Procaine. This reaction also requires precise control of parameters to ensure product quality.
3. Crystallization and Drying: Similar to the benzathine salt, crystallization and drying are critical for defining the physical properties and stability of Penicillin G Procaine.

Manufacturing Challenges:

• Fermentation Yield and Consistency: Maintaining high and consistent yields from fermentation is challenging due to biological variability. Contamination is a constant risk.
• Impurity Control: Degradation products of penicillins, as well as residual solvents, heavy metals, and by-products from synthesis, must be meticulously controlled to meet pharmacopoeial limits.
• Stability: Penicillins are susceptible to hydrolysis and degradation, particularly in the presence of moisture and heat. Manufacturing processes and storage conditions must be optimized to maintain stability.
• Allergenicity: Penicillins are known allergens. Strict containment and handling procedures are required during manufacturing to prevent cross-contamination and exposure of personnel.
• Scale-Up: Transitioning from laboratory-scale synthesis to large-scale industrial production requires significant process optimization to maintain yields, purity, and cost-effectiveness.
• Regulatory Hurdles: Obtaining and maintaining regulatory approvals in multiple jurisdictions requires significant investment in validation, documentation, and ongoing compliance.

How do the supply chains for Penicillin G Benzathine and Penicillin G Procaine differ?

While both Penicillin G Benzathine and Penicillin G Procaine are derived from Penicillin G, their supply chains exhibit some distinct characteristics due to the different amine bases used in their formation and the end-market applications.

Similarities:

• Upstream Source: Both rely on the initial fermentation of Penicillium chrysogenum to produce Penicillin G. This is a common bottleneck and a specialized manufacturing capability.
• Key Producers of Penicillin G: Manufacturers with established expertise in large-scale beta-lactam fermentation are the primary sources of the Penicillin G precursor for both salts.
• Regulatory Scrutiny: Both drug substances are subject to stringent cGMP regulations and pharmacopoeial standards.

Differences:

• Downstream Synthesis Expertise: The synthesis of the benzathine salt requires specific expertise in handling and reacting with N,N'-dibenzylethylenediamine, while the procaine salt requires expertise with procaine. These are distinct chemical processes, and not all penicillin manufacturers may have capabilities for both.
• Supplier Specialization: While some large integrated API manufacturers may produce both, it is also common for suppliers to specialize in one salt or the other, or to focus on specific markets.
• Geographical Concentration: While the fermentation base for Penicillin G is more globalized (with significant production in Europe and Asia), the suppliers for the specific salts can sometimes be more geographically concentrated. For instance, certain regions or specific companies might have a stronger historical foothold in producing one salt over the other.
• Market Demand Drivers: Penicillin G Benzathine is primarily used in long-acting injectable formulations (e.g., Bicillin L-A for syphilis treatment), which have specific market dynamics and demand patterns. Penicillin G Procaine is also used in injectable suspensions (e.g., Penicillin G Procaine for veterinary use and some human formulations) but may have different volume requirements and therapeutic niches.
• Formulation Complexity: The physical characteristics of the benzathine and procaine salts (e.g., particle size, crystal form) can impact their formulation into stable injectable suspensions. Manufacturers may tailor their synthesis to meet the specific needs of formulators.

Overall, while the core fermentation step is common, the chemical synthesis, purity profiles, and specific market demands lead to some differentiation in the supplier landscape and supply chain considerations for Penicillin G Benzathine versus Penicillin G Procaine.

What are the cost drivers and market trends for these drug substances?

The cost of Penicillin G Benzathine and Penicillin G Procaine drug substances is influenced by a combination of raw material costs, manufacturing complexity, regulatory compliance expenses, and market dynamics.

Key Cost Drivers:

• Raw Material Costs: The primary cost driver is the production of Penicillin G itself, which involves expensive fermentation media, energy-intensive processes, and specialized equipment. The cost and availability of the amine bases (N,N'-dibenzylethylenediamine for benzathine and procaine) also contribute.
• Manufacturing Complexity and Yields: Multi-step synthesis, stringent purification, and the inherent instability of penicillins increase manufacturing costs. Lower yields in fermentation or synthesis directly translate to higher per-kilogram costs.
• Regulatory Compliance: Adhering to cGMP, maintaining regulatory filings (e.g., DMFs), undergoing inspections, and implementing robust quality control systems represent significant ongoing expenses for manufacturers.
• Energy and Utilities: Fermentation and chemical synthesis are energy-intensive processes. Fluctuations in energy prices can impact manufacturing costs.
• Labor Costs: Skilled labor is required for fermentation operations, chemical synthesis, quality control, and regulatory affairs.
• Environmental Regulations: Compliance with environmental discharge regulations for fermentation waste and chemical processing can add to operational costs.

Market Trends:

• Stable, Mature Market: Penicillin G Benzathine and Penicillin G Procaine are established antibiotics with long histories. The market is mature and generally stable, with demand driven by established treatment protocols and existing drug formulations.
• Focus on Quality and Reliability: With the increasing scrutiny on pharmaceutical supply chains, there is a growing emphasis on suppliers with strong regulatory track records, robust quality management systems, and reliable supply. This often favors established players with significant investment in compliance.
• Geographical Shifts in Production: While Europe has historically been a strong producer of penicillins, there has been a significant shift in API manufacturing towards Asia, particularly India and China, due to lower labor and operational costs. However, concerns about supply chain resilience and quality are leading to renewed interest in diverse sourcing.
• Generic Competition: As these are older drugs, they face strong competition from generic manufacturers. This exerts downward pressure on API pricing, forcing suppliers to optimize costs.
• Limited New Entrants: The high capital investment required for fermentation facilities and the stringent regulatory barriers make it challenging for new manufacturers to enter the market, contributing to the consolidated supplier base.
• Supply Chain Resilience: Recent global events have highlighted the importance of supply chain resilience. Companies are increasingly looking for diversification of suppliers and geographical sourcing to mitigate risks of disruption. This can sometimes lead to price increases for more secure or dual-sourced materials.

The market for these drug substances is characterized by a balance between the cost pressures of mature generic markets and the increasing demands for quality, regulatory compliance, and supply chain security.

Which geographical regions are dominant in the supply of Penicillin G Benzathine and Penicillin G Procaine drug substances?

The global supply of Penicillin G Benzathine and Penicillin G Procaine drug substances is characterized by a significant presence in certain geographical regions, reflecting historical strengths in fermentation and chemical synthesis, as well as evolving manufacturing cost dynamics.

Dominant regions include:

• Europe: Historically, Europe has been a powerhouse for penicillin production. Countries like Austria (Sandoz) and the Netherlands (Centrient Pharmaceuticals) maintain significant manufacturing capabilities. These European sites often focus on high-quality, regulated API production for Western markets, leveraging decades of expertise and robust regulatory infrastructure.

• Asia (India and China): These regions have become dominant players in the global API market, including penicillins, due to their cost-competitive manufacturing environments and large-scale production capacities.

  • India: Companies like Taj Pharmaceuticals Limited are key suppliers, benefiting from a well-established pharmaceutical industry, a skilled workforce, and significant investment in API manufacturing that meets international standards.
  • China: Manufacturers such as Anhui Dejia-Bio Pharmaceutical Co., Ltd. and Qingdao EON PHARMA Co., Ltd. contribute substantially to the global supply. Chinese API production has scaled significantly, making them critical suppliers for both domestic and international markets.

Factors influencing regional dominance:

• Fermentation Infrastructure: The establishment of large-scale fermentation plants is a prerequisite for penicillin production. Regions with existing infrastructure and expertise in industrial biotechnology are naturally positioned.
• Cost of Production: Labor, energy, and environmental compliance costs play a significant role. Asia generally offers lower operational costs, driving a large portion of bulk API manufacturing.
• Regulatory Compliance Investment: While Asian manufacturers have scaled rapidly, the investment in meeting stringent FDA and EMA cGMP standards varies. European manufacturers often have a longer-established track record of compliance with these specific regulatory bodies.
• Government Support and Policy: Pharmaceutical manufacturing is often supported by government policies aimed at promoting domestic production and export.
• Supply Chain Dynamics: Global pharmaceutical companies source APIs from regions that offer a balance of quality, cost, and supply chain security. This has led to a dual sourcing strategy for many, utilizing both European and Asian suppliers.

While production is geographically dispersed, there is a clear concentration of large-scale manufacturing capacity in Europe and, increasingly, in Asia.

Key Takeaways

• The global supply of Penicillin G Benzathine and Penicillin G Procaine drug substances is concentrated among a select group of manufacturers, primarily located in Europe and Asia.
• Key suppliers include Sandoz GmbH (Austria), Centrient Pharmaceuticals (Netherlands), Taj Pharmaceuticals Limited (India), Anhui Dejia-Bio Pharmaceutical Co., Ltd. (China), and Qingdao EON PHARMA Co., Ltd. (China).
• Manufacturing requires adherence to stringent global regulatory standards, including cGMP, FDA, EMA, and pharmacopoeial specifications (USP, Ph. Eur.).
• Production involves complex fermentation of Penicillium chrysogenum followed by chemical synthesis of the respective salts, with challenges in yield consistency, impurity control, and product stability.
• Supply chains share common upstream fermentation but differ in downstream synthesis expertise, supplier specialization, and specific market demands for each salt.
• Cost drivers include raw materials, manufacturing complexity, regulatory compliance, and energy. Market trends indicate a mature, stable market with an increasing emphasis on quality, reliability, and supply chain resilience.
• Europe and Asia (India, China) are the dominant geographical regions for drug substance supply, driven by established infrastructure, cost efficiencies, and regulatory investment.

FAQs

1. What is the typical lead time for ordering Penicillin G Benzathine or Penicillin G Procaine drug substance from a major supplier? Lead times can vary significantly based on supplier inventory, production schedules, and order volume, but generally range from 8 to 24 weeks for custom or large-scale orders.

2. Are there any specific challenges in sourcing these drug substances for markets with less stringent regulatory requirements? While some markets have less stringent regulatory requirements, sourcing often still necessitates meeting pharmacopoeial standards and demonstrating adequate quality control to ensure product safety and efficacy, regardless of local regulations.

3. How does the stability of Penicillin G Benzathine and Penicillin G Procaine affect their shelf life as drug substances? Penicillin G salts are susceptible to degradation, impacting their shelf life. Manufacturers must control storage conditions (temperature, humidity) and provide detailed stability data, typically indicating a shelf life of 2-3 years under recommended storage.

4. What is the approximate annual global production volume for Penicillin G Benzathine and Penicillin G Procaine drug substances? Precise global production volumes are proprietary and fluctuate annually, but they are substantial, measured in metric tons, to meet the demand for established injectable antibiotics.

5. Can a single manufacturing facility produce both Penicillin G Benzathine and Penicillin G Procaine? Yes, large, integrated API manufacturers with expertise in both penicillin G production and subsequent salt formations can produce both drug substances, provided they maintain strict segregation and validated cleaning procedures to prevent cross-contamination.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (cGMP) Regulations. Retrieved from [FDA Website] [2] European Medicines Agency. (n.d.). Good manufacturing practice. Retrieved from [EMA Website] [3] United States Pharmacopeia. (n.d.). USP-NF. Retrieved from [USP Website] [4] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability. Retrieved from [EDQM Website] [5] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Harmonised Tripartite Guideline Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. Retrieved from [ICH Website] [6] Company Websites and Public Filings for Sandoz GmbH, Centrient Pharmaceuticals, Taj Pharmaceuticals Limited, Anhui Dejia-Bio Pharmaceutical Co., Ltd., and Qingdao EON PHARMA Co., Ltd. (Specific URLs omitted for brevity as these are dynamic and proprietary).